Skip to the page
pepts.wiki

We are not doctors and nothing here is medical advice. Always consult a medical professional first. Why we say this

Guides / Retatrutide

Retatrutide: what the trials measured

Body weight, blood sugar and liver fat in the published trials, arm by arm, with what is still unknown.

6 min read · 2026-11-17

Read this first

Every number here is an average across a group of screened and monitored trial participants. An average is not a forecast for one person, and an amount a protocol assigned is a fact about that study, not guidance for anyone.

Body weight

The phase 2 obesity trial enrolled 338 adults with a BMI of 30 or higher, or 27 to under 30 with a weight-related condition. They received a once-weekly injection of 1 mg, 4 mg, 8 mg or 12 mg, or placebo, for 48 weeks 1.

At 48 weeks the mean change in body weight was -24.2% in the 12 mg group against -2.1% on placebo. The effect grew with the amount assigned: -8.7% on 1 mg, -17.1% on 4 mg and -22.8% on 8 mg 1.

What the trials measured

Each bar is one arm of a published trial: the mean change in the group assigned that amount. Pick an outcome.

Change in body weight at 48 weeks

Change in body weight at 48 weeks
ArmMean change
Placebo (comparator)-2.1%
1 mg-8.7%
4 mg-17.1%
8 mg-22.8%
12 mg-24.2%

Least-squares mean percentage change from baseline in the phase 2 obesity trial, 338 adults. The 4 mg and 8 mg figures pool two arms that differed only in starting dose. [1]

Pink bars are comparator arms. Results of a trial are averages across a monitored group, not a forecast for a person.

Blood sugar

The phase 2 trial in type 2 diabetes enrolled 281 adults. At 24 weeks HbA1c had fallen by 2.02 percentage points on 12 mg, against 0.01 on placebo and 1.41 on dulaglutide 1.5 mg, which the trial used as a comparator. Body weight was down 16.94% at 36 weeks 2.

The phase 3 trial TRANSCEND-T2D-1 enrolled 537 adults whose type 2 diabetes was not controlled by diet and exercise. At 40 weeks HbA1c had fallen by 1.94 points and body weight by 15.3% on 12 mg, against 0.81 points and 2.6% on placebo 4.

Liver fat

A substudy followed 98 participants of the obesity trial who had liver fat of 10% or more on MRI. At 24 weeks the mean relative change in liver fat was -82.4% on 12 mg against +0.3% on placebo, and 86% of the 12 mg group reached normal liver fat 3.

What is still unknown

The longest published trial ran 48 weeks, so nothing published describes years of use 1. A trial in people with chronic kidney disease, TRANSCEND-CKD, has published its design and baseline but no results yet 9. A head-to-head trial against tirzepatide is registered and has not reported 12.

A 2025 systematic review pooled four placebo-controlled trials 7. Pooling adds precision. It does not add time: the pooled trials are the same short ones.

  1. Phase 1b: Multiple ascending dose 5

    72 people, 12 weeks

    Once-weekly subcutaneous injection in five ascending cohorts, the highest stepping 3, 6, 9 then 12 mg; placebo and dulaglutide 1.5 mg as comparators

    Half-life approximately 6 days; placebo-adjusted HbA1c down 1.2 to 1.6 points in the three highest groups; placebo-adjusted weight reduction up to 8.96 kg

  2. Phase 2: Obesity 1

    338 people, 48 weeks

    Once-weekly subcutaneous 1 mg, 4 mg, 8 mg or 12 mg, or placebo; the 4 mg and 8 mg arms started at 2 mg or 4 mg

    Body weight -24.2% on 12 mg against -2.1% on placebo at 48 weeks

  3. Phase 2: Type 2 diabetes 2

    281 people, 36 weeks

    Once-weekly 0.5 mg, 4 mg, 8 mg or 12 mg, placebo, or dulaglutide 1.5 mg

    HbA1c -2.02 points on 12 mg at 24 weeks against -0.01 on placebo and -1.41 on dulaglutide; body weight down 16.94% at 36 weeks

  4. Phase 2a: MASLD substudy 3

    98 people, 48 weeks

    Once-weekly 1 mg, 4 mg, 8 mg or 12 mg, or placebo

    Liver fat -82.4% on 12 mg against +0.3% on placebo at 24 weeks; 86% reached normal liver fat

  5. Phase 3: TRANSCEND-T2D-1 4

    537 people, 40 weeks

    Once-weekly 4 mg, 9 mg or 12 mg, or placebo

    HbA1c -1.94 points and body weight -15.3% on 12 mg, against -0.81 points and -2.6% on placebo

  6. Phase 2b: TRANSCEND-CKD 9

    146 people, 24 weeks

    Once-weekly at the maximum tolerated dose up to 12 mg, or placebo

    Design and baseline published; no results yet

Sources

The numbers are those of the Retatrutide page, where every source is listed.

  1. 1Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. The New England Journal of Medicine, 2023
  2. 2Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet, 2023
  3. 3Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine, 2024
  4. 4Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. The Lancet, 2026
  5. 7Tewari J, Qidwai KA, Tewari A, et al. Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis. Expert Review of Clinical Pharmacology, 2025
  6. 9Heerspink HJL, van Raalte DH, Bjornstad P, et al. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2026
  7. 12Eli Lilly and Company A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity. ClinicalTrials.gov, 2024
The full Retatrutide page

Read next